Table 1 Characteristics of MDS/CMML patients with positive or negative IPS
Positive IPS (n = 10) | Negative IPS (n = 11) | |
|---|---|---|
Sex ratio (M/W) | 5/5 (1) | 5/6 (0.83) |
Initial platelet count (n, min–max) | 49 (40–83) | 75 (41–91) |
Bleeding symptoms | 1 (10%) | 3 (27%) |
Isolated thrombocytopenia prior to MDS/CMML | 8 (80%) | 6 (54%) |
Interval between first thrombocytopenia and MDS/CMML in months (n, min–max) | 16 (1–77) | 20 (8–59) |
Age at diagnosis of MDS/CMML (n, min–max) | 68 (61–75) | 70 (70–77) |
Platelet count at diagnosis of MDS/CMML (× 109/L; n, min–max) | 42 (32–56) | 59 (44–75) |
Disease (MDS/CMML) | ||
CMML | 5 (50%) | 3 (27%) |
RAEB | 1 (10%) | 4 (37%) |
MDS-MLD | 2 (20%) | 1 (9%) |
MDS-U | 1 (10%) | 2 (18%) |
MDS-SLD | 1 (10%) | 1 (9%) |
Bone marrow cellularity | ||
Decreased | 0 (0%) | 2 (18%) |
Normal | 6 (60%) | 5 (45%) |
Increased | 4 (40%) | 4 (36%) |
Megakaryocytes in bone marrow | ||
Decreased | 1 (10%) | 5 (45%) |
Normal or increased | 9 (90%) | 6 (55%) |
Dysplastic megakaryocytesa | ||
Yes | 7 (70%) | 2 (18%) |
No | 3 (30%) | 9 (82%) |
R-IPSS | ||
Low | 5 (20%) | 4 (37%) |
Intermediate 1 | 4 (40%) | 6 (54%) |
Intermediate 2 | 1 (10%) | 1 (9%) |
High | 0 (0%) | 0 (0%) |
Presence of ANA | ||
No | 6 (60%) | 6 (54%) |
Yes | 4 (40%) | 4 (37%) |
Not performed | 0 (0%) | 1 (9%) |
MAIPA | ||
Positive | 1 (10%) | 1 (9%) |
Negative | 6 (60%) | 4 (37%) |
Not performed | 3 (30%) | 6 (54%) |
Platelet kinetic study | ||
Interval between first thrombocytopenia and IPS, months (n, min–max) | 22 (7–37) | 22 (4–41) |
Sequestration pattern | ||
None | 1 (10%) | 7 (64%) |
Splenic | 7 (70%) | 2 (18%) |
Hepatic | 2 (20%) | 2 (18%) |
Platelet lifespan (n, min–max) | 5.5 (5–6) | 7 (6.5–7) |